Cargando…
Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients
BACKGROUND: As proton pump inhibitors share CYP3A4 enzyme with tacrolimus for their hepatic elimination, they potentially affect its pharmacokinetics, most prominently in patients with CYP2C19 or CYP3A5 gene mutations. Our aim was to investigate the impact of omeprazole on tacrolimus pharmacokinetic...
Autores principales: | Katsakiori, Paraskevi F, Papapetrou, Eirini P, Goumenos, Dimitrios S, Nikiforidis, George C, Flordellis, Christodoulos S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893758/ https://www.ncbi.nlm.nih.gov/pubmed/20596503 |
Ejemplares similares
-
Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients
por: Katsakiori, Paraskevi F., et al.
Publicado: (2011) -
Factors affecting the long-term response to tacrolimus in renal transplant patients: Pharmacokinetic and pharmacogenetic approach
por: Katsakiori, Paraskevi F., et al.
Publicado: (2010) -
CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
por: Chen, Lucy, et al.
Publicado: (2018) -
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
por: Lunde, Ingrid, et al.
Publicado: (2014) -
CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients
por: Li, Yi, et al.
Publicado: (2015)